Zhaomiao Lin, Guoliang Li, Hong Zhang, Rongchang Ji, Yongqing Xu, Guochun Xu, Huawei Li, Zhonghua Liu, Wenbin Luo, Yongxiang Qiu, Sixin Qiu^*, Hao Tang

Phyton-International Journal of Experimental Botany, Vol.93, No.12, pp. 3401-3410, 2024, DOI:10.32604/phyton.2024.058692 - 31 December 2024

Abstract Sweet potato leaves are consumed globally for their nutritional and functional properties, with their taste characteristics significantly influencing their market value and consumer acceptance. However, the metabolic factors determining the taste of sweet potato leaves remain unclear. This study evaluated the taste and metabolic profile of sweet potato leaves cultivated in soil and hydroponic systems, revealing that hydroponic culture improved the taste of the leafy sweet potatoes. Using gas chromatography system (GC)-ToF-MS, 200 metabolites were identified, encompassing most plant metabolic pathways. A comparison of good-tasting vs. poor-tasting sweet potato leaves identified 71 metabolites associated with taste More >

Kevin R. Loughlin

Canadian Journal of Urology, Vol.28, No.2, pp. 10584-10588, 2021

Abstract Introduction: Five-alpha reductase (5-AR) deficiency was first identified by Imperato-McGinley and Walsh as the cause of pseudohermaphroditism in two separate studies. The discoveries led to the development of finasteride (inhibitor of type 2 isoenzyme of 5-AR) and dutasteride (inhibitor of type 1 and type 2 isoenzymes of 5-AR).
Both drugs have been proven effective for the treatment of benign prostatic hyperplasia, improving voiding symptoms, reducing the risk of urinary retention, and decreasing the need for prostate surgery.
Five-alpha reductase inhibitors (5-ARIs) have also been demonstrated to be chemopreventive agents, reducing the risk of prostate cancer, although the… More >

Chenggang Liang^1,#, Chunyu Wei^1,#, Yan Wang^1,*, Wujuan Yu¹, Kai Liao¹, Taoxiong Shi¹, Dabing Xiang^2,3, Qijiao Chen¹

Phyton-International Journal of Experimental Botany, Vol.90, No.3, pp. 871-893, 2021, DOI:10.32604/phyton.2021.014242 - 30 March 2021

Abstract Rice-Tartary buckwheat (RTB) is a special germplasm of Tartary buckwheat. In this study, the appraisal of taste quality between RTB and conventional Tartary buckwheat (CTB) was presented, and the metabolites in kernels at three typical grain filling stage (GFS) were investigated. Unlike CTB, RTB showed thin shell seeds without longitudinal furrows at maturity, which was easily artificially dehulled. Sense organ test indicated that RTB exhibited better taste quality because of the higher values of appearance, viscosity, taste and summary were appraised. In total, 92 metabolites were identified in kernels using GM-MS metabolomics platform. The levels… More >

Kristen E. Gurtner¹, Danica N. May¹, Jay D. Raman², Kathleen Lata-Arias¹, Daniel J. Canter¹

Canadian Journal of Urology, Vol.26, No.5, pp. 9931-9937, 2019

Abstract Introduction: There has been growing use of adrenalectomy as a potentially curative treatment option for patients with oligometastatic disease to the adrenal gland. We sought to compare the perioperative outcomes of patients undergoing isolated adrenalectomy in the setting of disseminated cancer using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. Furthermore, we examined the impact of performing surgical sub-specialty on outcomes.
Materials and methods: Data from the ACS-NSQIP database was obtained for patients between 2011 and 2016 who underwent adrenalectomy. Patients were stratified by the presence or absence of disseminated cancer. Univariate and… More >

Oliver Sartor¹, Leonard G. Gomella², Paul Gagnier³, Karen Melich³, Rebekkah Dann³

Canadian Journal of Urology, Vol.16, No.5, pp. 4806-4812, 2009

Abstract Introduction: Bicalutamide blocks androgen action in men with prostate cancer but has low affinity for the androgen receptor compared to dihydrotestosterone (DHT). Dutasteride, a dual 5α-reductase inhibitor (5ARI), blocks the conversion of testosterone to DHT, reduces tumor volume and improves PSA in prostate cancer. Bicalutamide should be a more effective antiandrogen if it competes against intraprostatic testosterone, rather than DHT, for the androgen receptor. The Therapy Assessed by Rising PSA (TARP) study investigates dutasteride in combination with bicalutamide to prevent or delay disease progression in patients with castrate-refractory prostate cancer (CRPC) after initial androgen deprivation therapy.
Patients… More >